# Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.

> **NCT02506777** · PHASE2 · UNKNOWN · sponsor: **N.N. Petrov National Medical Research Center of Oncology** · enrollment: 96 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** metformin
- **DRUG:** Fluoruracil
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** melatonin

## Key facts

- **NCT ID:** NCT02506777
- **Lead sponsor:** N.N. Petrov National Medical Research Center of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2020-08
- **Final completion:** 2020-08
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02506777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02506777, "Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02506777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*